Orion Portfolio Solutions LLC Has $638,000 Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Orion Portfolio Solutions LLC cut its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 2.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,237 shares of the medical research company’s stock after selling 67 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Charles River Laboratories International were worth $638,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Tortoise Investment Management LLC grew its stake in Charles River Laboratories International by 77.0% in the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after buying an additional 57 shares during the last quarter. Wolff Wiese Magana LLC acquired a new stake in Charles River Laboratories International in the 3rd quarter worth $32,000. Assetmark Inc. increased its holdings in shares of Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after purchasing an additional 173 shares during the period. Whittier Trust Co. of Nevada Inc. raised its position in shares of Charles River Laboratories International by 219.3% during the second quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock valued at $58,000 after buying an additional 193 shares during the last quarter. Finally, Covestor Ltd lifted its stake in shares of Charles River Laboratories International by 40.9% in the third quarter. Covestor Ltd now owns 327 shares of the medical research company’s stock valued at $65,000 after buying an additional 95 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 1.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

CRL has been the subject of several recent research reports. Robert W. Baird cut their price target on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a report on Friday, September 20th. UBS Group raised their target price on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Bank of America reduced their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price for the company. in a research report on Monday, November 18th. Finally, Redburn Atlantic initiated coverage on Charles River Laboratories International in a research report on Monday, October 14th. They issued a “sell” rating and a $151.00 target price for the company. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $214.00.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $189.39 on Wednesday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The stock has a fifty day moving average price of $194.42 and a two-hundred day moving average price of $202.68. Charles River Laboratories International, Inc. has a 52-week low of $176.48 and a 52-week high of $275.00. The firm has a market capitalization of $9.68 billion, a P/E ratio of 23.70, a P/E/G ratio of 5.00 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. During the same period in the prior year, the company posted $2.72 earnings per share. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. As a group, analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).